Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 10/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 16/20 | 0.48 |
| ▸ | PGR | P06401 | 5/20 | 0.44 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138367 | 0.89 | SLC6A2 (0.42) | NR3C2NR3C1PGRSLC13A5MEN1 | |
| SCHEMBL4138451 | 0.87 | NR3C1 (0.58) | NR3C2NR3C1PGR | |
| SCHEMBL4138205 | 0.86 | NR3C1 (0.61) | NR3C2NR3C1PGR | |
| SCHEMBL27754147 | 0.86 | NR3C1 (0.47) | NR3C2NR3C1PGRSLC13A5SMN1; SMN2 | |
| SCHEMBL3656645 | 0.85 | NR3C1 (0.45) | NR3C2NR3C1PGR | |
| SCHEMBL27774865 | 0.85 | NR3C1 (0.44) | NR3C2NR3C1PGRSLC13A5 | |
| SCHEMBL27774909 | 0.83 | NR3C1 (0.54) | NR3C2NR3C1PGRSLC13A5SMN1; SMN2 | |
| SCHEMBL27754136 | 0.82 | NR3C1 (0.53) | NR3C2NR3C1PGRSMN1; SMN2 | |
| SCHEMBL27774913 | 0.82 | NR3C1 (0.55) | NR3C2NR3C1PGRSLC13A5SMN1; SMN2 | |
| SCHEMBL4039578 | 0.82 | NR3C1 (0.71) | NR3C2NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1895999-A1 | USE OF NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | Schering Aktiengesellschaft (DE) | 2008-03-12 | — | — | EP | claimed |
| EP-1467982-B8 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA (US) | 2007-04-11 | — | — | EP | claimed |
| US-7189758-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | claimed |
| WO-2007022824-A1 | USE OF NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-01 | — | — | WO | claimed |
| US-20060293317-A1 | Use of non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | US | claimed |
| EP-1467982-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA (US) | 2006-11-22 | — | — | EP | claimed |
| US-20060030561-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | US | claimed |
| EP-1467982-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-20 | — | — | EP | claimed |
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | claimed |
| WO-2003059899-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| EP-2056799-B1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | BAUSCH & LOMB (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2203160-B1 | PHARMACOLOGICAL ADJUNCTIVE TREATMENT ASSOCIATED WITH GLAUCOMA FILTRATION SURGERY | BAUSCH & LOMB (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2190431-B1 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST FOR TREATING OR CONTROLLING ANTERIOR-SEGMENT INFLAMMATION | BAUSCH & LOMB (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2364707-B1 | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof | BAUSCH & LOMB (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | SOLTA MEDICAL IRELAND LIMITED (IE) | 2012-12-13 | — | — | US | disclosed |
| US-20060030561-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| US-6960581-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1467982-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003059899-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | NR3C1, NR3C2, MC2R | NR3C2 2/4885NR3C1 1/4885PGR 227/4885 |
| US-20060293317-A1 | Use of non-steroidal progesterone receptor modulators | SHBG, PGR, NR5A1 | NR3C2 17/4885NR3C1 32/4885PGR 2/4885 |
| US-20060030561-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | NR3C1, MC2R, NR3C2 | NR3C2 3/4885NR3C1 1/4885PGR 80/4885 |
| US-20120316199-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | PTGIR, MC2R, NR3C1 | NR3C2 18/4885NR3C1 3/4885PGR 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.